Publications by authors named "Mark J Salji"
Article Synopsis
- Castration-resistant prostate cancer (CRPC) is a challenging and incurable disease, prompting researchers to explore biological changes through multi-omics datasets.
- Using untargeted RNA sequencing, proteomics, and metabolomics, researchers analyzed human cell line models of CRPC and found significant biological markers associated with the disease.
- The study suggests that increased levels of NAA in CRPC may arise from the upregulation of specific enzymes, impacting crucial metabolic pathways involved in tumor growth.
Article Synopsis
- A study found that a protein called THEM6 makes prostate cancer harder to treat when patients use androgen-deprivation therapy (ADT).
- Removing THEM6 from cancer cells helped slow down tumor growth and made the cancer more sensitive to treatment again.
- High levels of THEM6 in patients are linked to worse survival, so targeting THEM6 could help improve treatments for advanced prostate cancer.
5-Fluorouracil (5-FU) is an antineoplastic antimetabolite that is widely administered to cancer patients by bolus injection, especially to those suffering from colorectal and pancreatic cancer. Because of its suboptimal route of administration and dose-limiting toxicities, diverse 5-FU prodrugs have been developed to confer oral bioavailability and increase the safety profile of 5-FU chemotherapy regimens. Our contribution to this goal is presented herein with the development of a novel palladium-activated prodrug designed to evade the metabolic machinery responsible for 5-FU anabolic activation and catabolic processing.
View Article and Find Full Text PDFAndrogen deprivation therapy (ADT) is the standard of care for treatment of nonresectable prostate cancer. Despite high treatment efficiency, most patients ultimately develop lethal castration-resistant prostate cancer (CRPC). In this study, we performed a comparative proteomic analysis of three , androgen receptor (AR)-responsive orthograft models of matched hormone-naïve prostate cancer and CRPC.
View Article and Find Full Text PDFBackground: Prostate cancer (PCa) is the second most common tumour diagnosed in men. Tumoral heterogeneity in PCa creates a significant challenge to develop robust prognostic markers and novel targets for therapy. An analysis of gene regulatory networks (GRNs) in PCa may provide insight into progressive PCa.
View Article and Find Full Text PDF